NVP-BGJ398 CAS: 872511-34-7

CAS NO: 872511-34-7
NVP-BGJ398
Chemical Name: NVP-BGJ398
Molecular Formula: C26H31Cl2N7O3
Formula Weight: 560.48
CAS No.: 872511-34-7
Description Review
Description

NVP-BGJ398 (also known as BGJ398) is a chemical compound that is used in scientific research as an inhibitor of fibroblast growth factor receptors (FGFRs). This inhibition has potential applications in treating certain medical conditions related to abnormal cell growth, such as cancer.

Chemical name: The chemical name of NVP-BGJ398 is 6-(2,6-Dichloro-3,5-dimethoxyphenyl)-4-(1-methylpiperidin-4-yl)pyrimidine-2-amine.

Molecular formula: The molecular formula of NVP-BGJ398 is C19H22Cl2N4O2.

Formula weight: The molecular weight of NVP-BGJ398 is 426.31 g/mol.

CAS No: The CAS number of NVP-BGJ398 is 872511-34-7.

Top ten keywords from Google and Synonyms:

  1. Cancer
  2. Fibroblast growth factor receptors (FGFRs)
  3. Abnormal cell growth
  4. Tumor cells
  5. Signal transduction
  6. Chemotherapy
  7. Targeted therapy
  8. Tyrosine kinase inhibitor
  9. Bladder cancer
  10. Lung cancer

Synonyms: • BGJ398 • NVP-BGJ-398 • Infigratinib • 6-(2,6-Dichloro-3,5-dimethoxyphenyl)-4-(1-methylpiperidin-4-yl)pyrimidine-2-amine

Health benefits of this product: NVP-BGJ398 inhibits the activity of fibroblast growth factor receptors (FGFRs), which play a role in various cellular processes like cell proliferation, differentiation, migration, and survival. By inhibiting FGFRs, NVP-BGJ398 can potentially affect these processes, leading to changes in cell behavior, including cell cycle arrest or apoptosis. This inhibition has potential applications in treating certain medical conditions related to abnormal cell growth, such as cancer.

Potential effects: NVP-BGJ398 inhibits the activity of fibroblast growth factor receptors (FGFRs), which play a role in various cellular processes like cell proliferation, differentiation, migration, and survival. By inhibiting FGFRs, NVP-BGJ398 can potentially affect these processes, leading to changes in cell behavior, including cell cycle arrest or apoptosis. This inhibition has potential applications in treating certain medical conditions related to abnormal cell growth, such as cancer.

Product mechanism: NVP-BGJ398 inhibits the activity of fibroblast growth factor receptors (FGFRs) by binding to the active site of the enzyme. FGFRs are involved in various cellular processes, including cell proliferation, differentiation, migration, and survival. By inhibiting FGFRs, NVP-BGJ398 can block these processes and potentially reduce abnormal cell growth.

Safety: NVP-BGJ398 is mainly used in scientific research and has not been approved for human use. Its safety in humans is not well established, and there may be potential side effects associated with its use. Individuals should seek advice from a healthcare professional before using NVP-BGJ398.

Side effects: The potential side effects of NVP-BGJ398 are not well-established as it is primarily used in scientific research. However, there may be potential risks associated with its use, including toxicity and effects on normal cell growth.

Dosing information: NVP-BGJ398 is mainly used in scientific research and dosing information is determined based on the specific experiment being performed. Individuals should consult with a qualified scientist or healthcare professional for guidance on appropriate dosing.

Conclusion: NVP-BGJ398 is a chemical compound that is commonly used in scientific research as an inhibitor of fibroblast growth factor receptors (FGFRs). The inhibition of FGFRs has potential applications in treating certain medical conditions related to abnormal cell growth, such as cancer. Although mainly used in scientific research, potential side effects and safety concerns should be taken into consideration if considering its use. Further studies are needed to determine the safety and efficacy of NVP-BGJ398 for human use.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us